Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine and Hydrocortisone for POAF Prevention in CABG
NCT05674253Phase 1Unknown
- Sponsor
- Ain Shams University
- Start
- Dec 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dexmedetomidine and hydrocortisone in Atrial fibrillation (AFib) (2 arms), sponsored by Ain Shams University. Primary endpoint: Occurrence of Atrial Fibrillation at 7 days. Status: unknown.
02
Drugs
dexmedetomidinehydrocortisone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05674253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05674253.